Ülo Kivistik

ÜK

Statistics

Publications

Citations

414

H-Index

Active since

2019

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Northwestern University

Délégation Paris 7

Université Paris Cité

North Estonia Medical Centre

Ülo Kivistik is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in ventilator-associated pneumonia treatment, nosocomial pneumonia, and bacterial pneumonia treatment.

Publications per year

2019–2021

Publications

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial

Marin H. Kollef, Martin Nováček, Ülo Kivistik et al. · The Lancet Infectious Diseases · 2019 · 346 citations

Pharmacy, Clinical Sciences, Infectious Diseases +16

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

Jean‐François Timsit, Jennifer A. Huntington, Richard G. Wunderink et al. · Critical Care · 2021 · 46 citations · Full text

Pharmacy, Pharmacotherapy, Antimicrobial Pharmacotherapy +14

Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia

Ignacio Martín‐Loeches, Jean‐François Timsit, Marin H. Kollef et al. · Journal of Antimicrobial Chemotherapy · 2021 · 22 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +17

1–3 of 3